While the reduction in the price target from $40 to $36 by Roth MKM could suggest a tempered outlook on First Wave BioPharma's short-term price potential, the maintenance of a Buy rating indicates continued confidence in the company's fundamentals. This mixed signal could lead to neutral short-term price movement as investors weigh the lowered price target against the reaffirmed positive rating.